OncoMatch/Clinical Trials/NCT05475106

Pilot Study of Neoantigen Peptides and Leukine for the Treatment of Neoplasms

Is NCT05475106 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Neoantigen Peptides for neoplasms.

Early Phase 1RecruitingInstituto de Medicina RegenerativaNCT05475106Data as of May 2026

Treatment: Neoantigen Peptides — The present study is a pilot clinical trial using personalized neoantigen peptide vaccines with the addition of Leukine (Sargramostim), in patients with different types of cancer.

Check if I qualify

Extracted eligibility criteria

Lab requirements

Blood counts

Lymphocyte ratio >20%; WBC >3.0×10^9/L; Normal blood coagulation function

Kidney function

BUN ≤1.5 × ULN; Creatinine ≤1.5 × ULN

Liver function

ALT and AST ≤2.5 × ULN (≤5 × ULN if liver metastases); ALP ≤2.5 × ULN; TBIL < 1.5 × ULN

Cardiac function

Normal electrocardiogram (ECG)

Have adequate organ function, as measured by laboratory values: Lymphocyte ratio >20%; WBC >3.0×10^9/L; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN; if the patient has liver metastases, ALT and AST ≤5 × ULN; Alkaline phosphatase (ALP）≤2.5 × ULN; total serum bilirubin (TBIL) < 1.5 × ULN; Urea nitrogen (BUN）≤1.5 × ULN; Creatinine (Cr）1.5≤ULN; Normal blood coagulation function, urine routine, and electrocardiogram (ECG)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify